GSK Reportedly Bidding For Turkish Biofarma, Local Manufacturing Key To Market Registration
This article was originally published in PharmAsia News
GlaxoSmithKline PLC is rumored to be among three final bidders for Turkish generic drug maker Biofarma Pharmaceutical Industry Co. Inc. MNCs in Turkey are stepping up plans to establish a local manufacturing presence in Turkey to respond to continued price pressure, according to analysts
You may also be interested in...
Biofarma, one of the dynamic actors in the challenging Turkish pharmaceutical market, put up a strong performance in 2012–13 and its owners are now looking to benefit. So far, information on a likely share sale by one or both of the firm’s two investors has not been released, but Biofarma is looking forward to new opportunities and as sales and marketing director Gurhan Kaba told PharmAsia News in an exclusive interview, “Biofarma is a platform ready to grow.”
Amgen Shrugs Off Turkish Price Cuts, Snatches Up Mustafa Nevzat For Broader Reach Into Emerging Markets
Despite harsh price cuts in Turkey that have taken a toll on multinationals, Amgen dives head first into the market.
Sanofi Sees Strength In Regional Volatility, GSK Lowers Revenue Target After Price Cuts – Emerging Market Earnings Roundup (Part 4)
In a recurring feature, PharmAsia News combs through quarterly earnings reports to bring you highlights on emerging markets.